Peripheral blood lymphocyte subset shifts in patients with untreated hematological tumors: Evidence for systemic activation of the T cell compartment

Alterations of the expression of T-cell-related costimulatory CD28 and downregulatory CD152 (CTLA-4) molecules in patients with B-cell chronic lymphocytic leukaemia

“…Rossi et al (1996) found a significant decrease in CD28 molecules on T cells in 33 patients with B-CLL. Similar results were obtained by Van den Hove et al (1998) increased the mean proportion of CD2 þ /CD152 þ from 1.972.7 to 6.875.1%. In the present study, we demonstrated for the first time abnormal levels and a different kinetics pattern of costimulatory CD28 and inhibitory CD152 molecules expression on ex vivo-stimulated CD3 þ /CD4 þ and CD3 þ /CD8 þ PB T cells in B-CLL patients compared with healthy controls.…”

“…The CD28 molecule is lost by normal lymphocytes after repeated stimulation with IL-2 in long-term culture (Labalette et al, 1999). Based on the fact that T lymphocytes from B-CLL patients have a phenotype of activated cells, that is, Dianzani et al, 1994;Van den Hove et al, 1998;Scrivener et al, 2001), it can be suggested that the loss of CD28 molecule on T lymphocytes before culture is related to a prolonged in vivo activation of these cells. Our finding of a markedly increased expression of the inducible suppressory CD152 molecule on freshly drawn CD4 þ and CD8 þ T cells in B-CLL patients strengthens the suggestion that T cells in B-CLL are in a partial state of activation.…”

“…Little is known about CD28 and CD152 expression on peripheral blood (PB) T cells in patients with B-CLL. To the best of our knowledge, only three papers have been published on the expression of these molecules in B-CLL patients so far (Rossi et al, 1996;Van den Hove et al, 1998;Scrivener et al, 2001). Our study was designed to evaluate the kinetics and expression of CD28 and CD152 on unstimulated and anti -CD3 þ rIL-2-stimulated CD4 þ and CD8 þ T lymphocytes from B-CLL patients.…”

CD57+/CD28− T cells in untreated hemato-oncological patients are expanded and display a Th1-type cytokine secretion profile, ex vivo cytolytic activity and enhanced tendency to apoptosis

“…Despite the expansion of the CD28 − subset among CD8 + T cells of hemato-oncological patients and the significant correlation of cytotoxicity with the CD28 − subset in CD8 + T cells of both patients and donors, CD8 + T cells of patients and donors display similar cytotoxic activities. 33 This suggests that the expanded CD8 + CD28 − / CD57 + T cell subset in hemato-oncological patients either has a lower cytolytic potential on a per cell basis than in healthy controls, or that it rapidly progresses to apoptosis upon triggering (see below), or that it contains an important fraction of cells with other than cytotoxic functions. Relevant to the latter possibility, regulatory or suppressive functions by CD8 + CD57 + /CD28 − T cells have been described by several groups.…”

Identifying the Target Cell in Primary Simian Immunodeficiency Virus (SIV) Infection: Highly Activated Memory CD4+T Cells Are Rapidly Eliminated in Early SIV Infection In Vivo

“…To assess lymphocyte activation and distinguish naive from memory T cells, a variety of antibodies against cell surface markers were used in various combinations, based on current knowledge of T-cell activation and memory (Table 1). Activation markers included CD69, a cell surface antigen expressed very early in T-cell activation (59), CD28, a costimulatory molecule important in T-cell activation and cytokine regulation (6,15,26,28,51), CD38, a transmembrane glycoprotein thought to be involved in T-cell signaling, activation, and adhesion (2,32,42), and HLA-DR (a major histocompatibility complex type II [MHC II] molecule), which is also upregulated on activated lymphocytes. To distinguish naive from memory CD4…”